Michael Johnson, MD
Ophthalmology · Charleston, SCNPI 1548203185
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (48.9%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 75.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $5,533 and has fallen 87.5% since, to $691 in 2025.
Across 62 payments — averaging $137.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$6K
- Regeneron Healthcare Solutions, Inc.$400
- Genentech USA, Inc.$275
- Eyepoint US, Inc.$182
- Harrow Eye, LLC$179
- Apellis Pharmaceuticals, Inc.$170
- plus $882 from 14 others
Across 1 payment — averaging $14,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$14K
What the payments were for
- Food & beverage$2,08925%
- Ownership interest$2,25727%
- Other$4,15749%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $6,414 |
| Regeneron Healthcare Solutions, Inc. | 14 | $400 |
| Genentech USA, Inc. | 9 | $275 |
| Eyepoint US, Inc. | 6 | $182 |
| Harrow Eye, LLC | 3 | $179 |
| Apellis Pharmaceuticals, Inc. | 2 | $170 |
| Genentech, Inc. | 1 | $150 |
| Alcon | 1 | $124 |
| AbbVie(2 entities) | 4 | $113 |
| Boston Scientific | 1 | $109 |
| Coherus Oncology, Inc. | 3 | $73 |
| Optos, Inc. | 1 | $63 |
| Biogen | 2 | $46 |
| Novartis | 2 | $42 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Dutch Ophthalmic, USA | 1 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $17 |
| Sandoz | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$282
- Syfovre$142
- IHEEZO$129
- Constellation$124
- YUTIQ$113
How this compares
$8,504 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 129 | $6,676 |
| Alphagan PBrimonidine Tartrate | 18 | $4,874 |
| Brimonidine Tartrate | 270 | $4,574 |
| Latanoprost | 354 | $3,499 |
| Acetazolamide | 25 | $2,710 |
| Ofloxacin | 74 | $1,343 |
| Atropine Sulfate | 33 | $1,271 |
| Dorzolamide Hcl | 54 | $954 |
| Brinzolamide | 12 | $910 |
| Ketorolac Tromethamine | 19 | $840 |
| Timolol Maleate | 84 | $724 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P | $113 | $4,87418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Charleston
- Karolinne RochaCharleston$552K
- Drew DicksonCharleston$53K
- Mona CamacciCharleston$26K
- Cole MillikenCharleston$17K
- Daniel AlfaroCharleston$15K
- Karen FernandezCharleston$13K
- John KerrisonCharleston$12K
- Eric JablonCharleston$12K
- Marion WilsonCharleston$9K
- Berdine BurgerCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.